Spinogenix Launches Phase II Trial for Synaptic Regenerative Therapy in Schizophrenia
Novel Schizophrenia Drug Explored; Daridorexant Treats Insomnia + Nocturia; ADHD Drug Trialed
Spinogenix’s ALS Breakthrough: A Los Angeles-Based Biotech’s Bold Leap Forward
FDA Authorizes Expanded Access Program for ALS Treatment SPG302
Inside A Bold New Approach To Alzheimer’s
Reset the Clock on Schizophrenia: SPG302, A Regenerative Treatment
Behind the Steering Wheel of Your Brain: Residual Negative and Cognitive Symptoms in Schizophrenia
Phase 2 Trial Open Enrollment for SPG302, First Synaptic Regenerative Approach to Treat Schizophrenia
SPG302: A Synaptic Regenerative Treatment Option for Schizophrenia
SPG601 found to reduce measure of abnormal brain activity in fragile X
